Arcturus Therapeutics Holdings/$ARCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Ticker
$ARCT
Sector
Primary listing
Employees
109
Headquarters
Website
ARCT Metrics
BasicAdvanced
$209m
-
-$2.84
2.43
-
Price and volume
Market cap
$209m
Beta
2.43
52-week high
$24.17
52-week low
$5.85
Average daily volume
433k
Financial strength
Current ratio
6.31
Quick ratio
6.189
Long term debt to equity
10.284
Total debt to equity
12.535
Interest coverage (TTM)
-9,818.33%
Profitability
EBITDA (TTM)
-85.483
Gross margin (TTM)
-80.67%
Net profit margin (TTM)
-143.80%
Operating margin (TTM)
-161.52%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
-19.14%
Return on equity (TTM)
-37.01%
Valuation
Price to revenue (TTM)
3.728
Price to book
1.09
Price to tangible book (TTM)
1.09
Price to free cash flow (TTM)
-3.477
Free cash flow yield (TTM)
-28.76%
Free cash flow per share (TTM)
-2.117
Growth
Revenue change (TTM)
-61.92%
Earnings per share change (TTM)
12.62%
3-year revenue growth (CAGR)
-42.04%
3-year earnings per share growth (CAGR)
-11.41%
What the Analysts think about ARCT
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
ARCT Financial Performance
Revenues and expenses
ARCT Earnings Performance
Company profitability
ARCT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs